Reports to Medarex. During the Term, Celldex shall keep Medarex informed of its development and commercialization activities subject to this Agreement with respect to Royalty-Bearing Products, including the filing of an IND or the initiation of a clinical trial, and on January 31 of each year shall provide Medarex with a reasonably detailed written summary of such events and activities in the preceding year.
Reports to Medarex. During the term of this Agreement, Celldex shall keep Medarex informed of its development and commercialization activities subject to this Agreement, and on January 31 of each year shall provide Medarex with a reasonably detailed written summary of such events and activities in the preceding year. When the registration package requesting Approval for commercial sale of any Product receives Approval [*****], Celldex will notify Medarex in writing within ten (10) business days thereof.
Reports to Medarex. During the term of this Agreement, Genmab shall keep Medarex fully informed of its activities subject to this Agreement, including without limitation, the commercialization of Products, and on [***] of each year shall provide Medarex with a written report detailing such events and activities. When the registration package requesting approval for commercial sale of the Product (including approval for reimbursement by the appropriate health insurance authorities as well as price approvals where required) is first filed in [***], and in each case when approval is received therefor, Genmab will notify Medarex in writing within [***] days.
Reports to Medarex. During the term of this Agreement, FibroGen shall keep Medarex reasonably informed of its activities subject to this Agreement, including without limitation, the commercialization of Products, and annually shall provide Medarex with a written report detailing such events and activities. When the registration package requesting approval for commercial sale of the Product is first filed in the U.S., the European Union and Japan, and in each case when approval is received therefor, FibroGen will promptly notify Medarex in writing.
Reports to Medarex. During the term of this Agreement, Leukosite shall ------------------ keep Medarex fully informed of its activities subject to this Agreement, including without limitation, the commercialization of Products, and on January 31 of each year shall provide Medarex with a written report detailing such events and activities. When the registration package requesting approval for commercial sale of the Product is first filed in the U.S., the European Union and Japan, and in each case when approval is received therefor, Leukosite will notify Medarex in writing within [*****] days.
Reports to Medarex. During the term of this Agreement, Centeon shall -------------------- keep Medarex fully informed of its activities subject to this Agreement, including without limitation, the achievement of the milestones set forth in Section 4.3 and the commercialization of the Product, and following January 31 of each year shall provide Medarex with a written report detailing such events and activities. When the registration package requesting approval for commercial sale of the Product (including approval for reimbursement by the appropriate health insurance authorities as well as price approvals where required) is first filed in the U.S., the European Union and Japan, and in each case when approval is received therefor, Centeon will notify Medarex in writing immediately by facsimile.
Reports to Medarex. During the term of this Agreement, EOS shall keep ------------------ Medarex fully informed of its development and commercialization activities subject to this Agreement, ***** REPRESENTS CONFIDENTIAL PORTION WHICH HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. and on January 31 of each year shall provide Medarex with a written report detailing such events and activities in the preceding year. When the registration package requesting Approval for commercial sale of any Product receives Approval in each of the U.S., the first country in the European Union and Japan, EOS will notify Medarex in writing within [*****] days.
Reports to Medarex. During the term of this Agreement, Immunex shall ------------------ keep Medarex informed of its development and commercialization activities subject to this Agreement, and on January 31 of each year shall provide Medarex with a written summary of such events and activities in the preceding year. When the registration package requesting Approval for commercial sale of any Product receives Approval in the U.S., Europe and Japan, Immunex will notify Medarex in writing within [*****] days thereof.
Reports to Medarex. During the term of this Agreement, ErythroMed ------------------ shall keep Medarex fully informed of its activities subject to this Agreement, including without limitation, the commercialization of Products, and on January 31 of each year shall provide Medarex with a written report detailing such events and activities. When the registration package requesting approval for commercial sale of the Product (including approval for reimbursement by the appropriate health insurance authorities as well as price approvals where required) is first filed in the U.S., the European Union and Japan, and in each case when approval is received therefor, ErythroMed will notify Medarex in writing within [*****].
Reports to Medarex. During the term of this Agreement, ------------------ Novartis shall keep Medarex informed of its development and commercialization activities subject to this Agreement, and on January 31 of each year shall provide Medarex with a written summary of such events and activities in the preceding year. When the registration package requesting Approval for commercial sale of any Product receives Approval in the U.S., Europe and Japan, Novartis will notify Medarex in writing within ten (10) business days thereof.
